Comparative Pharmacology
Head-to-head clinical analysis: BUTENAFINE HYDROCHLORIDE versus GRISACTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTENAFINE HYDROCHLORIDE versus GRISACTIN.
BUTENAFINE HYDROCHLORIDE vs GRISACTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Binds to microtubules and disrupts mitotic spindle formation, inhibiting fungal cell division.
1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.
500 mg orally once daily or 250 mg orally twice daily for dermatophyte infections.
None Documented
None Documented
Terminal elimination half-life is approximately 35–40 hours following topical application; long half-life supports once-daily dosing.
Terminal elimination half-life: 9–24 hours (mean ~14 hours). Clinical context: Steady-state achieved in 3–5 days; once-daily dosing is effective due to prolonged half-life.
Primarily metabolized in the liver; minimal excretion of unchanged drug. Less than 5% of a topical dose is absorbed systemically; excreted in urine and feces as metabolites.
Renal: <1% as intact drug; fecal: >99% as metabolites (mainly 6-demethylgriseofulvin glucuronide) via bile; negligible biliary excretion of parent compound.
Category C
Category C
Antifungal
Antifungal